JP2018500351A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500351A5 JP2018500351A5 JP2017533901A JP2017533901A JP2018500351A5 JP 2018500351 A5 JP2018500351 A5 JP 2018500351A5 JP 2017533901 A JP2017533901 A JP 2017533901A JP 2017533901 A JP2017533901 A JP 2017533901A JP 2018500351 A5 JP2018500351 A5 JP 2018500351A5
- Authority
- JP
- Japan
- Prior art keywords
- trans
- phenyl
- amino
- cyclohexyl
- phenylpyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 2,2-difluoro - cyclobutyl Chemical group 0.000 claims 108
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 82
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 78
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 72
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 49
- 150000001875 compounds Chemical class 0.000 claims 38
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 22
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 13
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 150000001408 amides Chemical class 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- PMDCZENCAXMSOU-UHFFFAOYSA-N N-ethylacetamide Chemical compound CCNC(C)=O PMDCZENCAXMSOU-UHFFFAOYSA-N 0.000 claims 4
- 150000001204 N-oxides Chemical class 0.000 claims 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000006239 protecting group Chemical group 0.000 claims 4
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- PDUSWJORWQPNRP-UHFFFAOYSA-N n-propan-2-ylacetamide Chemical compound CC(C)NC(C)=O PDUSWJORWQPNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- OVPLZYJGTGDFNB-UHFFFAOYSA-N propan-2-yl carbamate Chemical compound CC(C)OC(N)=O OVPLZYJGTGDFNB-UHFFFAOYSA-N 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- CZNMWVKSUHZBFO-NDEPHWFRSA-N (2S)-N-[6-[4-(1-aminocyclobutyl)phenyl]-5-phenylpyridin-3-yl]-2-(1-cyclopropylsulfonylpiperidin-4-yl)-2-fluoroacetamide Chemical compound NC1(CCC1)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC([C@@H](F)C1CCN(CC1)S(=O)(=O)C1CC1)=O)C1=CC=CC=C1 CZNMWVKSUHZBFO-NDEPHWFRSA-N 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 1
- PZKFSRWSQOQYNR-UHFFFAOYSA-N 5-methyl-1h-1,2,4-triazole Chemical compound CC1=NC=NN1 PZKFSRWSQOQYNR-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- GZQCNKLHJGROSH-LSNLESRRSA-N CC(C)(C(C=C1)=CC=C1C(N=CC(NC(C[C@H](CC1)CC[C@@H]1C1(CC1)C(NC)=O)=O)=C1)=C1C1=CSC=C1)N Chemical compound CC(C)(C(C=C1)=CC=C1C(N=CC(NC(C[C@H](CC1)CC[C@@H]1C1(CC1)C(NC)=O)=O)=C1)=C1C1=CSC=C1)N GZQCNKLHJGROSH-LSNLESRRSA-N 0.000 claims 1
- RUHKIZONSLCQQU-SAIGFBBZSA-N CC(C)(C(C=CC(C(N=CC(NC(C[C@H](CC1)CC[C@@H]1C1(CC1)C(NC)=O)=O)=C1)=C1C1=CC=CC=C1)=C1)=C1F)N Chemical compound CC(C)(C(C=CC(C(N=CC(NC(C[C@H](CC1)CC[C@@H]1C1(CC1)C(NC)=O)=O)=C1)=C1C1=CC=CC=C1)=C1)=C1F)N RUHKIZONSLCQQU-SAIGFBBZSA-N 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010070666 Cortical dysplasia Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000000676 Malformations of Cortical Development Diseases 0.000 claims 1
- CZNMWVKSUHZBFO-UHFFFAOYSA-N N-[6-[4-(1-aminocyclobutyl)phenyl]-5-phenylpyridin-3-yl]-2-(1-cyclopropylsulfonylpiperidin-4-yl)-2-fluoroacetamide Chemical compound NC1(CCC1)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C(F)C1CCN(CC1)S(=O)(=O)C1CC1)=O)C1=CC=CC=C1 CZNMWVKSUHZBFO-UHFFFAOYSA-N 0.000 claims 1
- BPTYSEQNBGWNGL-SAIGFBBZSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)C(=O)N(C)C)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)C(=O)N(C)C)=O)C1=CC=CC=C1 BPTYSEQNBGWNGL-SAIGFBBZSA-N 0.000 claims 1
- ILGQWBUQSFQCIG-UEZMCPDZSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(=O)C1(CC1)C)C)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(=O)C1(CC1)C)C)=O)C1=CC=CC=C1 ILGQWBUQSFQCIG-UEZMCPDZSA-N 0.000 claims 1
- MOIDMCWTMRRKPD-RSIILCRJSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(=O)C1CC1)C)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(=O)C1CC1)C)=O)C1=CC=CC=C1 MOIDMCWTMRRKPD-RSIILCRJSA-N 0.000 claims 1
- IQEKYNZTCAGIRC-CBHYQUCXSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(=O)C1CCC1)C)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(=O)C1CCC1)C)=O)C1=CC=CC=C1 IQEKYNZTCAGIRC-CBHYQUCXSA-N 0.000 claims 1
- TZTAVZIIXYKXTC-WBANQOEISA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(C(F)F)=O)C)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(C(F)F)=O)C)=O)C1=CC=CC=C1 TZTAVZIIXYKXTC-WBANQOEISA-N 0.000 claims 1
- OJUDESRDBLNACR-YLIUREIVSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC(C)(C)C)=O)C)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC(C)(C)C)=O)C)=O)C1=CC=CC=C1 OJUDESRDBLNACR-YLIUREIVSA-N 0.000 claims 1
- JCJQNAIUBJHNIP-MGFGWZDJSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC)=O)C)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC)=O)C)=O)C1=CC=CC=C1 JCJQNAIUBJHNIP-MGFGWZDJSA-N 0.000 claims 1
- NTXYABYPCHJOKJ-CBHYQUCXSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC1CC1)=O)C)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC1CC1)=O)C)=O)C1=CC=CC=C1 NTXYABYPCHJOKJ-CBHYQUCXSA-N 0.000 claims 1
- YMOFWKGIIVXKNI-PGWJBFNOSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(=O)C1(CC1)C)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(=O)C1(CC1)C)=O)C1=CC=CC=C1 YMOFWKGIIVXKNI-PGWJBFNOSA-N 0.000 claims 1
- HKVXAZXPGOADMW-WVPZODRTSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(=O)C1CC1)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(=O)C1CC1)=O)C1=CC=CC=C1 HKVXAZXPGOADMW-WVPZODRTSA-N 0.000 claims 1
- LEXRAADIBWTDQU-OGAOHHHESA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(=O)C1CC1)=O)C1=CSC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(=O)C1CC1)=O)C1=CSC=C1 LEXRAADIBWTDQU-OGAOHHHESA-N 0.000 claims 1
- HZXLPBUTFBJTDJ-MGFGWZDJSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(=O)C1CCC1)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(=O)C1CCC1)=O)C1=CC=CC=C1 HZXLPBUTFBJTDJ-MGFGWZDJSA-N 0.000 claims 1
- QWTWVTWTHRAUDQ-PGWJBFNOSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(C)(C)C)=O)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(C)(C)C)=O)=O)C1=CC=CC=C1 QWTWVTWTHRAUDQ-PGWJBFNOSA-N 0.000 claims 1
- GTDBLOQVDUSUPL-PGWJBFNOSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(C)C)=O)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(C)C)=O)=O)C1=CC=CC=C1 GTDBLOQVDUSUPL-PGWJBFNOSA-N 0.000 claims 1
- QXLSOFQVJDPRBY-JIBACQESSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(CC(C)(C)C)=O)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(CC(C)(C)C)=O)=O)C1=CC=CC=C1 QXLSOFQVJDPRBY-JIBACQESSA-N 0.000 claims 1
- BRRCICUHYQRSMH-WVPZODRTSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(N=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(=O)C1CC1)C)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(N=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(=O)C1CC1)C)=O)C1=CC=CC=C1 BRRCICUHYQRSMH-WVPZODRTSA-N 0.000 claims 1
- JRGLQGSMSWPLEZ-MGFGWZDJSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(N=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(=O)C1CCC1)C)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(N=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(=O)C1CCC1)C)=O)C1=CC=CC=C1 JRGLQGSMSWPLEZ-MGFGWZDJSA-N 0.000 claims 1
- FGYOSLKCDHVOAJ-OKDASEJXSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(N=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC)=O)C)=O)C1=CC=CC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(N=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC)=O)C)=O)C1=CC=CC=C1 FGYOSLKCDHVOAJ-OKDASEJXSA-N 0.000 claims 1
- VUFIKWVVZJXSAH-UILWBTOOSA-N NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(N=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC)=O)C)=O)C1=CSC=C1 Chemical compound NC(C)(C)C1=CC=C(C=C1)C1=C(C=C(N=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC)=O)C)=O)C1=CSC=C1 VUFIKWVVZJXSAH-UILWBTOOSA-N 0.000 claims 1
- YZUBXDKTGDGXNA-CFEHLUOOSA-N NC1(CC(C1)(C)O)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(F)F)=O)=O)C1=CC=CC=C1 Chemical compound NC1(CC(C1)(C)O)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(F)F)=O)=O)C1=CC=CC=C1 YZUBXDKTGDGXNA-CFEHLUOOSA-N 0.000 claims 1
- LLUJTWWKFSCZQY-OKDASEJXSA-N NC1(CC1)C1=C(C=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC)=O)C)=O)C1=CC=CC=C1)F Chemical compound NC1(CC1)C1=C(C=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC)=O)C)=O)C1=CC=CC=C1)F LLUJTWWKFSCZQY-OKDASEJXSA-N 0.000 claims 1
- JVXGNWUQDNNPIR-JKIUYZKVSA-N NC1(CC1)C1=C(C=C(C=C1)C1=C(C=C(N=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC)=O)C)=O)C1=CC=CC=C1)F Chemical compound NC1(CC1)C1=C(C=C(C=C1)C1=C(C=C(N=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC)=O)C)=O)C1=CC=CC=C1)F JVXGNWUQDNNPIR-JKIUYZKVSA-N 0.000 claims 1
- XPFCOUUHTVOLDY-XGAFWQRZSA-N NC1(CC1)C1=C(C=C(C=C1)C1=C(C=C(N=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC)=O)C)=O)C1=CSC=C1)F Chemical compound NC1(CC1)C1=C(C=C(C=C1)C1=C(C=C(N=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC)=O)C)=O)C1=CSC=C1)F XPFCOUUHTVOLDY-XGAFWQRZSA-N 0.000 claims 1
- BLTYRKHMOICZLB-PGWJBFNOSA-N NC1(CC1)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(C)(C)C)=O)=O)C1=CC=CC=C1 Chemical compound NC1(CC1)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(C)(C)C)=O)=O)C1=CC=CC=C1 BLTYRKHMOICZLB-PGWJBFNOSA-N 0.000 claims 1
- SMCFWMPUQJDNNN-UILWBTOOSA-N NC1(CC1)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(F)F)=O)=O)C1=CC=CC=C1 Chemical compound NC1(CC1)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(F)F)=O)=O)C1=CC=CC=C1 SMCFWMPUQJDNNN-UILWBTOOSA-N 0.000 claims 1
- NJHLBVZTUBSWBO-PGWJBFNOSA-N NC1(CC1)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(CCC)=O)=O)C1=CC=CC=C1 Chemical compound NC1(CC1)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(CCC)=O)=O)C1=CC=CC=C1 NJHLBVZTUBSWBO-PGWJBFNOSA-N 0.000 claims 1
- IIPKJDNGADIKGH-WVPZODRTSA-N NC1(CC1)C1=CC=C(C=C1)C1=C(C=C(N=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(=O)C1CC1)C)=O)C1=CC=CC=C1 Chemical compound NC1(CC1)C1=CC=C(C=C1)C1=C(C=C(N=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(=O)C1CC1)C)=O)C1=CC=CC=C1 IIPKJDNGADIKGH-WVPZODRTSA-N 0.000 claims 1
- IVSWGRWWUJVABZ-MGFGWZDJSA-N NC1(CC1)C1=CC=C(C=C1)C1=C(C=C(N=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(=O)C1CCC1)C)=O)C1=CC=CC=C1 Chemical compound NC1(CC1)C1=CC=C(C=C1)C1=C(C=C(N=N1)NC(C[C@@H]1CC[C@H](CC1)N(C(=O)C1CCC1)C)=O)C1=CC=CC=C1 IVSWGRWWUJVABZ-MGFGWZDJSA-N 0.000 claims 1
- XRRYTSNNLXKHHU-MGFGWZDJSA-N NC1(CCC1)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(=O)C1CC1)=O)C1=CC=CC=C1 Chemical compound NC1(CCC1)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(=O)C1CC1)=O)C1=CC=CC=C1 XRRYTSNNLXKHHU-MGFGWZDJSA-N 0.000 claims 1
- FVUMQGGKRANKCQ-OKDASEJXSA-N NC1(CCC1)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(C)(C)C)=O)=O)C1=CSC=C1 Chemical compound NC1(CCC1)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(C)(C)C)=O)=O)C1=CSC=C1 FVUMQGGKRANKCQ-OKDASEJXSA-N 0.000 claims 1
- YBFURIVPVRXULX-LSNLESRRSA-N NC1(CCC1)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(F)F)=O)=O)C1=CC=CC=C1 Chemical compound NC1(CCC1)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(F)F)=O)=O)C1=CC=CC=C1 YBFURIVPVRXULX-LSNLESRRSA-N 0.000 claims 1
- NLLXDMOQSTYBFR-OKDASEJXSA-N NC1(CCC1)C1=CC=C(C=C1)C1=NC=C(C=C1C=1C=NC=CC=1)NC(C[C@@H]1CC[C@H](CC1)NC(C(C(F)(F)F)(C)C)=O)=O Chemical compound NC1(CCC1)C1=CC=C(C=C1)C1=NC=C(C=C1C=1C=NC=CC=1)NC(C[C@@H]1CC[C@H](CC1)NC(C(C(F)(F)F)(C)C)=O)=O NLLXDMOQSTYBFR-OKDASEJXSA-N 0.000 claims 1
- WMGMHOIBZMPNEJ-UEZMCPDZSA-N NC1(CCC1)C1=CC=C(C=C1)C=1C(=CC(=NC=1)NC(C[C@@H]1CC[C@H](CC1)N(C(=O)C1CC1)C)=O)C1=CC=CC=C1 Chemical compound NC1(CCC1)C1=CC=C(C=C1)C=1C(=CC(=NC=1)NC(C[C@@H]1CC[C@H](CC1)N(C(=O)C1CC1)C)=O)C1=CC=CC=C1 WMGMHOIBZMPNEJ-UEZMCPDZSA-N 0.000 claims 1
- IRBHCYRHPHXADF-RZFKFIIISA-N NC1(CCC1)C1=CC=C(C=C1)C=1C(=CC(=NC=1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC)=O)C)=O)C1=C(C=CC=C1)F Chemical compound NC1(CCC1)C1=CC=C(C=C1)C=1C(=CC(=NC=1)NC(C[C@@H]1CC[C@H](CC1)N(C(CC)=O)C)=O)C1=C(C=CC=C1)F IRBHCYRHPHXADF-RZFKFIIISA-N 0.000 claims 1
- KLVWSBQEJCLKPU-OKDASEJXSA-N NC1(COC1)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(C(F)(F)F)(C)C)=O)=O)C1=CC=CC=C1 Chemical compound NC1(COC1)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(C(F)(F)F)(C)C)=O)=O)C1=CC=CC=C1 KLVWSBQEJCLKPU-OKDASEJXSA-N 0.000 claims 1
- PNSYFUUKBZWHGU-WATLYSKOSA-N N[C@@H](C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(C(F)(F)F)(C)C)=O)=O)C1=CC=CC=C1 Chemical compound N[C@@H](C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(C(F)(F)F)(C)C)=O)=O)C1=CC=CC=C1 PNSYFUUKBZWHGU-WATLYSKOSA-N 0.000 claims 1
- PNSYFUUKBZWHGU-DNRQZRRGSA-N N[C@H](C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(C(F)(F)F)(C)C)=O)=O)C1=CC=CC=C1 Chemical compound N[C@H](C)C1=CC=C(C=C1)C1=C(C=C(C=N1)NC(C[C@@H]1CC[C@H](CC1)NC(C(C(F)(F)F)(C)C)=O)=O)C1=CC=CC=C1 PNSYFUUKBZWHGU-DNRQZRRGSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000023397 cerebral cortical dysplasia Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- GGFKQOQFSGPWBG-UHFFFAOYSA-N n-(2,2,2-trifluoroethyl)acetamide Chemical compound CC(=O)NCC(F)(F)F GGFKQOQFSGPWBG-UHFFFAOYSA-N 0.000 claims 1
- UHNHTTIUNATJKL-UHFFFAOYSA-N n-methylmethanesulfonamide Chemical compound CNS(C)(=O)=O UHNHTTIUNATJKL-UHFFFAOYSA-N 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 208000009999 tuberous sclerosis Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 208000029257 vision disease Diseases 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- TZDFCQQFICPDHL-UHFFFAOYSA-N CCC(C(C)C1CCC(CC(Nc2nnc(-c3ccc(C(C4)(CC4=[F])N)cc3)c(-c3ccccc3)c2)=O)CC1)=O Chemical compound CCC(C(C)C1CCC(CC(Nc2nnc(-c3ccc(C(C4)(CC4=[F])N)cc3)c(-c3ccccc3)c2)=O)CC1)=O TZDFCQQFICPDHL-UHFFFAOYSA-N 0.000 description 1
- FDFNITYLYNNGMR-VCCPSZSWSA-N CCC(CC(CC)=O)[C@H]1CC[C@H](CC(Nc2ncc(-c3ccc([C@](C4)(C[C@@]4(C)O)N)cc3)c(-c3ccccc3)c2)=O)CC1 Chemical compound CCC(CC(CC)=O)[C@H]1CC[C@H](CC(Nc2ncc(-c3ccc([C@](C4)(C[C@@]4(C)O)N)cc3)c(-c3ccccc3)c2)=O)CC1 FDFNITYLYNNGMR-VCCPSZSWSA-N 0.000 description 1
- 0 C[C@](C1)(C[C@@]1(c(c(F)c1)ccc1-c1cnc(CCNC(C[C@](CC2)CC[C@@]2N(C)C(C)=*)=O)cc1-c1ccccc1)N)O Chemical compound C[C@](C1)(C[C@@]1(c(c(F)c1)ccc1-c1cnc(CCNC(C[C@](CC2)CC[C@@]2N(C)C(C)=*)=O)cc1-c1ccccc1)N)O 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201423087 | 2014-12-23 | ||
| GB1423087.4 | 2014-12-23 | ||
| GB1508787.7 | 2015-05-22 | ||
| GBGB1508787.7A GB201508787D0 (en) | 2014-12-23 | 2015-05-22 | Pharmaceutically active compounds |
| GB1519919.3 | 2015-11-11 | ||
| GBGB1519919.3A GB201519919D0 (en) | 2015-11-11 | 2015-11-11 | Pharmaceutically active compounds |
| PCT/EP2015/081168 WO2016102672A2 (en) | 2014-12-23 | 2015-12-23 | Pharmaceutically active compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020139060A Division JP2020189880A (ja) | 2014-12-23 | 2020-08-20 | 医薬的活性化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500351A JP2018500351A (ja) | 2018-01-11 |
| JP2018500351A5 true JP2018500351A5 (enExample) | 2019-01-10 |
| JP6787899B2 JP6787899B2 (ja) | 2020-11-18 |
Family
ID=56151566
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533901A Expired - Fee Related JP6787899B2 (ja) | 2014-12-23 | 2015-12-23 | 医薬的活性化合物 |
| JP2020139060A Pending JP2020189880A (ja) | 2014-12-23 | 2020-08-20 | 医薬的活性化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020139060A Pending JP2020189880A (ja) | 2014-12-23 | 2020-08-20 | 医薬的活性化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10336702B2 (enExample) |
| EP (1) | EP3240784A2 (enExample) |
| JP (2) | JP6787899B2 (enExample) |
| KR (1) | KR20170115042A (enExample) |
| CN (1) | CN107207472B (enExample) |
| AU (1) | AU2015370911B2 (enExample) |
| CA (1) | CA2971763A1 (enExample) |
| WO (1) | WO2016102672A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016073738A2 (en) * | 2014-11-05 | 2016-05-12 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| US10336702B2 (en) * | 2014-12-23 | 2019-07-02 | Bergenbio Asa | Pharmaceutically active compounds |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CN108884061B (zh) | 2017-01-13 | 2021-11-16 | 江苏恒瑞医药股份有限公司 | 1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用 |
| CN111989313A (zh) * | 2018-02-15 | 2020-11-24 | 杭州阿诺生物医药科技有限公司 | A2a和/或a2b受体拮抗剂 |
| EP3794352A1 (en) | 2018-05-14 | 2021-03-24 | BerGenBio ASA | Serum biomarkers |
| CN111171065A (zh) * | 2020-02-26 | 2020-05-19 | 上海博黑生物科技有限公司 | 一种(4-(1-((叔丁氧基羰基)氨基)环丙基)苯基)硼酸酯的合成方法 |
| AU2021268345A1 (en) | 2020-05-05 | 2022-11-10 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| CN115916196A (zh) * | 2020-05-05 | 2023-04-04 | 纽威伦特公司 | 杂芳族大环醚化学治疗剂 |
| KR102853833B1 (ko) * | 2020-12-21 | 2025-09-02 | 동우 화인켐 주식회사 | 양자점, 양자점 분산체, 광변환 경화성 조성물, 컬러필터, 광변환 적층기재 및 화상표시장치 |
| WO2025066935A1 (en) * | 2023-09-28 | 2025-04-03 | Hepaitech (Beijing) Biopharma Technology Co., Ltd. | Compounds, compositions and methods thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6486199B1 (en) * | 2001-06-21 | 2002-11-26 | Medicines For Malaria Venture Mmv International Centre Cointrin | Spiro and dispiro 1,2,4-trioxolane antimalarials |
| WO2005085227A1 (en) * | 2004-03-02 | 2005-09-15 | Smithkline Beecham Corporation | Inhibitors of akt activity |
| CA2561311A1 (en) * | 2004-04-09 | 2005-10-27 | Merck & Co., Inc. | Inhibitors of akt activity |
| ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| GB0922589D0 (en) * | 2009-12-23 | 2010-02-10 | Almac Discovery Ltd | Pharmaceutical compounds |
| JP6403219B2 (ja) * | 2012-12-07 | 2018-10-10 | ベナトルクス ファーマシューティカルズ，インク． | ベータ−ラクタマーゼ阻害剤 |
| US10336702B2 (en) * | 2014-12-23 | 2019-07-02 | Bergenbio Asa | Pharmaceutically active compounds |
-
2015
- 2015-12-23 US US15/533,048 patent/US10336702B2/en active Active
- 2015-12-23 AU AU2015370911A patent/AU2015370911B2/en not_active Ceased
- 2015-12-23 CA CA2971763A patent/CA2971763A1/en active Pending
- 2015-12-23 JP JP2017533901A patent/JP6787899B2/ja not_active Expired - Fee Related
- 2015-12-23 KR KR1020177019939A patent/KR20170115042A/ko not_active Ceased
- 2015-12-23 EP EP15823511.9A patent/EP3240784A2/en not_active Withdrawn
- 2015-12-23 CN CN201580075417.7A patent/CN107207472B/zh not_active Expired - Fee Related
- 2015-12-23 WO PCT/EP2015/081168 patent/WO2016102672A2/en not_active Ceased
-
2019
- 2019-05-15 US US16/412,590 patent/US10766861B2/en not_active Expired - Fee Related
-
2020
- 2020-07-14 US US16/928,142 patent/US20210070708A1/en not_active Abandoned
- 2020-08-20 JP JP2020139060A patent/JP2020189880A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500351A5 (enExample) | ||
| JP2015502335A5 (enExample) | ||
| RU2454405C2 (ru) | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина | |
| JP6364472B2 (ja) | 抗がんおよび抗増殖活性を示すｎ−アシル−ｎ’−（ピリジン−２−イル）尿素および類似体 | |
| RU2017145650A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2010538076A5 (enExample) | ||
| JP2005526723A5 (enExample) | ||
| JP2018531981A5 (enExample) | ||
| JP2010539110A5 (enExample) | ||
| JP2019520416A5 (enExample) | ||
| JP2018529650A5 (enExample) | ||
| CN1428145A (zh) | 用作速激肽nk3受体拮抗剂的喹啉衍生物 | |
| JP2015522036A5 (enExample) | ||
| JP2011520896A5 (enExample) | ||
| EP2477976A1 (en) | Quinazolinone derivatives as viral polymerase inhibitors | |
| JP2019521109A5 (enExample) | ||
| AR089134A1 (es) | Arilos y heteroarilos biciclicos inhibidores de los canales de sodio | |
| CN105705489A (zh) | 用作免疫调节剂的化合物 | |
| JP2017533968A5 (enExample) | ||
| JP2014506599A5 (enExample) | ||
| JP2014507455A5 (enExample) | ||
| JP2014508128A5 (enExample) | ||
| WO2014145029A2 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2019505595A5 (enExample) | ||
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ |